Bumps May Grind Female Sex Pill's Sales
This article was originally published in Scrip
Executive Summary
While privately held Sprout Pharmaceuticals has insisted one in every 10 American women have hypoactive sexual desire disorder (HSDD) – meaning there could potentially be several million eligible for the firm's newly approved female sex pill Addyi (flibanserin) – the roadblocks the FDA has thrown up in front of the product could potentially damage its sales, no matter how much hype has revolved around it.